Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer

NCT03990194 ·Status: WITHDRAWN

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

NCT03085095 ·Status: COMPLETED ·Phase: PHASE3

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

NCT00220194 ·Status: COMPLETED ·Phase: PHASE4

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

NCT00128531 ·Status: COMPLETED ·Phase: PHASE3

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer

NCT02212197 ·Status: COMPLETED ·Phase: PHASE2

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

NCT03261999 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer

NCT03348527 ·Status: COMPLETED ·Phase: PHASE2

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

NCT00455624 ·Status: COMPLETED

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

NCT00514917 ·Status: TERMINATED ·Phase: PHASE3

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

NCT00817739 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

NCT02083185 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

NCT02085252 ·Status: COMPLETED ·Phase: PHASE3

Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer

NCT00520052 ·Status: COMPLETED ·Phase: NA

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

NCT03093272 ·Status: TERMINATED ·Phase: PHASE2

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

NCT05605964 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

NCT00001266 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

NCT06809426 ·Status: COMPLETED ·Phase: NA

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

NCT02499848 ·Status: COMPLETED ·Phase: PHASE2

Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448

NCT01132404 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

NCT02508636 ·Status: TERMINATED ·Phase: PHASE2

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903 ·Status: COMPLETED ·Phase: NA

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

NCT06970119 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Insulin Resistance Following ADT for Prostate CA

NCT04658849 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

NCT06783829 ·Status: RECRUITING ·Phase: PHASE1

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00937768 ·Status: TERMINATED ·Phase: PHASE2